Skip to Main ContentSkip to FooterSkip to Search
Contact Us
Contact Us
Main menu
  1. Home
    2.  » 
  2. About Us
    3.  » 
  3. Our Board of Directors
    4.  » Tim Walbert

Tim Walbert

Alessandro Masselli's headshot

TIM WALBERT

Tim Walbert served as the Chairman, President and Chief Executive Officer of Horizon Therapeutics from 2008 to October 2023, when it was acquired by Amgen for $28.3 billion. Before joining Horizon, he held various executive leadership positions across biotech and pharma companies, including  at Abbott, now AbbVie, leading the global development and launch of the multi-indication biologic HUMIRA. Mr. Walbert serves on the boards of directors of Biomarin, Century Therapeutics and Sagimet Biosciences, all public biotech companies and Cour Pharmaceuticals, Odyssey Therapeutics and Latigo Therapeutics (chairman), all private clinical-stage biotech companies. Mr. Walbert received a Bachelor of Arts in Business from Muhlenberg College in Allentown, PA and now serves as a member of the College’s Board of Trustees.